Cite
Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
MLA
Boch, Tobias, et al. “Safety and Efficacy of the CD95-Ligand Inhibitor Asunercept in Transfusion-Dependent Patients with Low and Intermediate Risk MDS.” Leukemia Research, vol. 68, May 2018, pp. 62–69. EBSCOhost, https://doi.org/10.1016/j.leukres.2018.03.007.
APA
Boch, T., Luft, T., Metzgeroth, G., Mossner, M., Jann, J.-C., Nowak, D., Meir, F. L., Schumann, C., Klemmer, J., Brendel, S., Fricke, H., Kunz, C., Weiß, C., Hofmann, W.-K., & Nolte, F. (2018). Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS. Leukemia Research, 68, 62–69. https://doi.org/10.1016/j.leukres.2018.03.007
Chicago
Boch, Tobias, Thomas Luft, Georgia Metzgeroth, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, Franziska La Meir, et al. 2018. “Safety and Efficacy of the CD95-Ligand Inhibitor Asunercept in Transfusion-Dependent Patients with Low and Intermediate Risk MDS.” Leukemia Research 68 (May): 62–69. doi:10.1016/j.leukres.2018.03.007.